This inventor holds 9 USPTO granted patents and 4 published patent applications. Top assignees: Bristol-Myers Squibb Compnay, Hoffmann-La Roche Inc.. Active years: 2014-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mahwah, NJ (US) (2014 - 2024)
- Princeton, NJ (US) (2024)
Company Filing History:
Years Active: 2014-2024
Title: Achal Mukundrao Pashine: Innovator in Therapeutic Antibodies
Introduction
Achal Mukundrao Pashine is a notable inventor based in Mahwah, NJ (US). He has made significant contributions to the field of therapeutic antibodies, holding a total of 9 patents. His work focuses on innovative solutions for autoimmune diseases, showcasing his expertise and dedication to advancing medical science.
Latest Patents
Among his latest patents are "Nucleic acids encoding anti-TREM-1 antibodies" and "Anti-TREM-1 antibodies and uses thereof." These patents describe antibodies that specifically bind and inhibit TREM-1 signaling. Importantly, these antibodies do not bind to one or more FcγRs and do not induce myeloid cells to produce inflammatory cytokines. The therapeutic applications of these antibodies are aimed at treating autoimmune diseases, highlighting their potential impact on patient care.
Career Highlights
Achal has worked with prominent companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and Hoffmann-La Roche Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of immunology.
Collaborations
Throughout his career, Achal has collaborated with esteemed colleagues such as Guodong Chen and Aaron Paul Yamniuk. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in therapeutic research.
Conclusion
Achal Mukundrao Pashine is a distinguished inventor whose work in therapeutic antibodies is paving the way for new treatments for autoimmune diseases. His contributions to the field are invaluable, and his ongoing research continues to inspire advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

